ORION CORPORATION STOCK EXCHANGE RELEASE
The publication dates of the Interim Reports and the Half-Year Financial Report in 2022 are as follows:
Interim Report January-March 2022 Half-Year Financial Report January- Interim Report January- | Thursday, Friday, Thursday, |
The Financial Statements and the Report of the Board of Directors for 2021 will be published on the Company's website at the latest in week 9/2022.
The Annual General Meeting is planned to be held on Wednesday,
Orion's financial reports and related presentation material are available on the Group's website at http://www.orion.fi/investors promptly after the publishing. The website also provides a possibility to register on Orion's mailing lists for releases.
President and CEO | SVP, Corporate Functions |
Contact person:
tel. +358 10 426 2721
Publisher:
Communications
Orionintie 1A, FI-02200 Espoo,
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to
© OMX, source